消息面上，国产创新药行业起步虽晚，当前已逐渐步入成熟期。截至2024年三季报，多个创新药行业龙头步入盈亏平衡，核心产品销售放量，“出海”交易频现，国际认可度持续提升。2024年11月27日，港股市场震荡上涨，港股创新药板块涨幅居前。指数成份股中，诺诚健华涨8.28%，科伦博泰生物-B涨5.17%，百济神州涨4.40%。港股创新 ...

Discover how ADCs are advancing oncology, the regulatory challenges they face, and the promise they hold for the future of ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...

Previously, NMPA has accepted two supplemental new drug applications (sNDA) seeking the approvals of sac-TMT monotherapy for the treatment of patients with locally advanced or metastatic EGFR-mutant ...

Denmark-based Adcendo is the latest biotech to secure funding in the antibody-drug conjugate (ADC) space, raising $135m to ...

Cancer treatment has entered a revolutionary phase with advancements in immunotherapy, a field that employs the immune system ...